EUCTR2009-013442-86-BE进行中（未招募）不适用
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female = 18 years of age
- •2.Chronic HCV infection for at least 6 months prior to Baseline (Day 1) documented by
- •a positive anti-HCV antibody test, positive HCV RNA assay, or HCV genotype test at least 6 months prior to Baseline (Day 1) and currently positive for HCV RNA and anti-HCV antibody, or
- •currently anti-HCV antibody positive and positive for HCV RNA and a liver biopsy performed = 6 months prior to Baseline (Day 1) with evidence of HCV infection
- •3.Liver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis. If a liver biopsy performed more than 1 year prior to Screening indicates Stage 3 fibrosis, the medical monitor must be consulted prior to enrollment (i.e., consensus must be reached that progression to cirrhosis with hepatic impairment is unlikely to have occurred in the time interval from liver biopsy to enrollment).
- •4.HCV treatment-naive, defined as no prior exposure to PEG, RIBA, any interferon alfa, or experimental HCV therapy
- •5.Mono-infection with HCV genotype 1
- •6.Detectable plasma HCV RNA at Screening
- •7.BMI between 18 and 36 kg/m2
- •8.Subjects must have the following laboratory parameters: hemoglobin
- •= 12 g/dL for females and = 13 g/dL for males, platelets = 90,000/mm3, white blood cell count > 2,500 cells/microlitre, neutrophils > 1500/mm3 (unless considered a physiologic variant discussed with and approved by the Gilead Medical Monitor), potassium and magnesium within normal limits, and TSH within normal limits (unless currently being treated for hypothyroidism in which case the medical monitor must be consulted prior to enrollment)
- •9.Creatinine clearance (CLcr) = 50 mL/min
- •10.Willing and able to provide written informed consent and to comply with all study requirements
- •11.Has not been treated with any investigational drug within 45 days of the randomization visit in this study.
- •12.Of generally good health as determined by the Investigator, based upon physical examination, laboratory parameters, ECG findings, vital signs, and medical history; physical examination must be inclusive of retinal exam (e.g., opthalmoscopic or slit lamp evaluation)
- •13.Women of childbearing potential (i.e., a non-menopausal female or a female with menopausal < 2 years, who has not had a hysterectomy, bilateral oophorectomy or medically documented ovarian failure) must have negative serum beta-human chorionic gonadotropin (hCG) at screening and negative urine beta-hCG at Baseline (Day 1) prior to the first study drug administration. Female subjects of childbearing potential and male subjects with a female partner of childbearing potential must agree that they and their partner will use effective contraception (two separate forms of contraception simultaneously, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence or have a vasectomized partner) from screening throughout the duration of study treatment and for at least 7 months after the last dose of RIBA.
- •Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
- •Female subjects who are postmenopausal for less than two years are required to have FSH = 40 mIU/mL. If the FSH is < 40 mIU/mL, the subject must agree to use highly effective method of birth control (as described above) to participate in the stud
排除标准
- •1.Pregnant women or women who may wish to become pregnant during the course of the study
- •2.Males who have partners who are pregnant or are planning to become pregnant
- •3.Males and females of reproductive potential who are unwilling to use two forms of effective birth control throughout the duration of study treatment and for at least 7 months after the last dose of RIBA. One method should include a condom with spermicide for males.
- •4.Infection with non-genotype 1 HCV
- •5.Poorly controlled diabetes mellitus (hemoglobin A1c > 9) unless treatment intervention has been reviewed with the Gilead Medical Monitor and improved glucose control is anticipated
- •6.History of hemoglobinopathy (e.g. thalassemia)
- •7.History of known retinal disease
- •8.History of sarcoidosis
- •9.History of invasive malignancy diagnosed or treated within 5 years (recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to screen); subjects under evaluation for malignancy are not eligible
- •10.Suspicion of hepatocelluar carcinoma; if alpha-fetoprotein > 50 ng/mL, enrollment is only allowed if results of appropriate diagnostic studies are inconsistent with a diagnosis of hepatocellular tumor
- •11.Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, cholangitis)
- •12.Decompensated liver disease defined as conjugated bilirubin > 1.5 x ULN, prothrombin time (PT) > 1.5 x ULN, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation (e.g. ascites, jaundice, encephalopathy, variceal hemorrhage)
- •13.Untreated or significant psychiatric illnesses including severe depression, schizophrenia, or psychosis, or a history of a suicide attempt
- •14.Co-infection with HIV or HBV
- •15.Chronic use of systemic immunosuppressive agents
- •16.Use of any prohibited concomitant medications
- •17.Presence of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, psoriasis of greater than mild severity). Subjects with hypothyroidism whose TSH is controlled on medication may be enrolled.
- •18.Severe chronic obstructive pulmonary disease (e.g., FEV1 < 1.5 L, or a daily requirement for inhaled bronchodilators or corticosteroids)
- •19.History of significant cardiac disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, or dilated cardiomyopathy with left ventricular ejection fraction < 40% ) or a family history of Long QT Syndrome. The following ECG abnormalities at screening are exclusionary: QTcF (QT corrected using Fridericia’s formula) of > 450 msec; QRS > 120 msec (left or right hemiblock is not exclusionary); bradycardia (< 45 beats per minute); second or third degree heart block. A history of clinically significant coronary artery disease without prior myocardial infarction will require consultation with a cardiologist and the medical monitor prior to enrollment
- •20.Positive urine screen for amphetamines, cocaine, opiate (i.e. heroin, morphine), or methadone use
- •21.Ongoing alcohol abuse in the judgment of the investigator (e.g., excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males) or current binge drinking
- •22.Receiving a known potent CYP 3A4 inhibitor within 2 weeks of study drug dosing or are expected to receiv
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
Efficacy and safety of Cabozantinib (XL184) in subjects who have progressed after VEGFR-targeted treatmentRadioiodine-Refractory Differentiated Thyroid Cancer which has progressed after priorVEGFR-targeted therapyMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001771-21-CZExelixis, Inc.300
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800